← 產業報告目錄

GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-10-21頁數 456報告編號 PH9080

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period. The GLP-1 agonists market has expanded rapidly due to several key drivers. One prominent factor is the growing number of new indication approvals for GLP-1 drugs by regulatory agencies. These approvals extend the uses of GLP-1 agonists beyond initial indications, allowing for treatments in broader patient populations, including newer indications such as cardiovascular conditions, Alzheimer’s disease, obstructive sleep apnea, and obesity. The rising prevalence of these chronic conditions globally further supports strong market growth, as more patients require effective therapies for diabetes and obesity. In parallel, GLP-1 agonists offer proven clinical benefits such as improved glycemic control and significant weight reduction, increasing their adoption rates among healthcare providers. The patented products segment accounted for the largest share of the GLP-1 agonists market by type in 2024. Based on type, the GLP-1 agonists market is segmented into patented products and biosimilars. In 2024, the patented products accounted for the largest share of the market. As biosimilars are expected to gain adoption post-2026, patented products currently account for the complete market. However, with the semaglutide patent expiring in 2026 onwards, the market for biosimilars is expected to grow significantly thereafter. Patented GLP-1 agonists dominate prescribing patterns due to their robust clinical data, extensive safety profiles, and premium marketing investments. Additionally, the original GLP-1 makers have established broad insurance coverage, ensuring patient access despite high list prices. These factors are expected to support market growth. By end user, the home-care settings and fitness/ weight management facilities accounted for the largest share in the GLP-1 agonists market in 2024. Based on end user, the GLP-1 agonists market is segmented into home-care settings and fitness/ weight management facilities, long-term care facilities, and hospitals & specialty clinics. In 2024, the home-care settings and fitness/weight management facilities segment accounted for the largest share of the GLP-1 agonists market. The large share of this end-user segment can be attributed to the evolving patient needs and broader trends in obesity and diabetes management. Home care settings offer convenience and flexible dosing schedules for patients, especially as most GLP-1 therapies are available in easy-to-administer, subcutaneous or oral formats. This increases patient adherence, with many preferring to self-administer medications, particularly for long-term therapies targeting obesity and type 2 diabetes. The spike in obesity prevalence and the mainstreaming of preventive health have also made GLP-1 usage in home environments much more common, driving share growth in this segment. The US dominated the GLP-1 agonists market in 2024. In 2024, the US dominated the GLP-1 agonists market due to a convergence of demographic, healthcare, regulatory, and commercial factors. The US has one of the highest prevalence rates globally for both obesity and type 2 diabetes, which significantly expands the patient pool eligible for GLP-1 treatment. Advanced healthcare infrastructure and widespread physician awareness ensure swift adoption of new therapies, while robust insurance coverage and reimbursement help broad patient access. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply-side- 70% and Demand-side 30% • By Designation: Managers - 45%, CXOs & Directors - 30%, and Executives - 25% • By Region: North America - 40%, Europe -25%, Asia Pacific -25%, Latin America -5% and the Middle East & Africa- 5% List of Companies Profiled in the Report: • Novo Nordisk A/S (Denmark) • Eli Lilly and Company (US) • Sanofi (France) • Hansoh Pharmaceutical Group Co., Ltd. (China) • Boehringer Ingelheim International GmbH (Germany) • Innovent (China) • Sun Pharmaceutical Industries Ltd. (India) • Pegbio Co. Ltd (China) • Structure Therapeutics (US) • Viking Therapeutics (US) • Amgen Inc. (Switzerland) • Altimmune (US) • Glenmark (India) • Biocon (India) • Teva Pharmaceuticals (Israel) • Terns Pharmaceuticals, Inc. (US) • VTV Therapeutics (US) • F. Hoffmann-La Roche Ltd (Switzerland) • Hanmi Pharm Co., Ltd. (South Korea) • Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China) • Pfizer Inc. (US) • MetaVia Inc (US) • SCOHIA PHARMA, Inc. (Japan) • Sciwind Biosciences Co., Ltd. (China) • i2o Therapeutics, Inc. (US) • Biomed Industries, Inc. (US) • Neuraly Inc. (US) Research Coverage This research report categorizes the GLP-1 agonists market by product (ozempic, wegovy, mounjaro, zepbound, rybelsus, trulicity, orforglipron, cagrisema, survodutide, retatrutide, semaglutide biosimilars, other GLP-1 biosimilars, other products), molecule (Semaglutide, Tirzepatide, Dulaglutide, Cagrilintide semaglutide combination, Orforglipron, Survodutide, Retatrutide, Other molecules), type (patented, biosimilars), format (single-dose, multi-dose, tablets), indication (diabetes, obesity, other indications), route of administration (subcutaneous, oral), end user (home-care settings and fitness/ weight management facilities, long-term care facilities, and hospitals and specialty clinics) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report's scope covers detailed information regarding the leading factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the GLP-1 agonists market. A thorough analysis of the key industry players has provided insights into their business overview, products offered, key strategies, collaborations, partnerships, and agreements. Product launches & approvals, expansions, acquisitions, partnerships, product pipelines, collaborations, and agreements are the recent developments associated with the GLP-1 agonists market. Key Benefits of Buying the Report The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall GLP-1 agonists market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (expanding manufacturing capacity, shift of GLP-1 drugs from diabetes specialty to broader treatment option, growing prevalence of obesity and type 2 diabetes), restraints (stringent cost and payer controls), opportunities (increasing studies on oral GLP-1), and challenges (counterfeits and compounded GLP-1 gray market, safety, tolerability, persistence issues) influencing the growth of the market. • Product Development/Innovation: Detailed insights on newly approved and launched products of the GLP-1 agonists market • Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions. • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the GLP-1 agonists market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of key players, including Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France), among other players. A detailed analysis of the key industry players has been conducted to provide insights into their key strategies, product approvals and launches, acquisitions, partnerships, agreements, collaborations, expansions, recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 agonists market.
目錄 Table of Contents
1 INTRODUCTION 42 1.1 STUDY OBJECTIVES 42 1.2 MARKET DEFINITION 42 1.3 STUDY SCOPE 43 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 43 1.3.2 INCLUSIONS & EXCLUSIONS 44 1.3.3 YEARS CONSIDERED 45 1.3.4 CURRENCY CONSIDERED 46 1.4 STAKEHOLDERS 46 1.5 SUMMARY OF CHANGES 46 2 RESEARCH METHODOLOGY 48 2.1 RESEARCH DATA 48 2.1.1 SECONDARY DATA 48 2.1.1.1 Key objectives of secondary research 49 2.1.2 PRIMARY DATA 49 2.1.2.1 Breakdown of primaries 50 2.1.2.2 Key objectives of primary research 50 2.2 MARKET SIZE ESTIMATION 51 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH) 51 2.2.2 SECONDARY DATA & PRIMARY INTERVIEWS 52 2.2.3 SEGMENTAL MARKET SIZE ASSESSMENT 53 2.3 MARKET GROWTH FORECAST 54 2.4 DATA TRIANGULATION 55 2.5 STUDY ASSUMPTIONS 56 2.6 RISK ANALYSIS 57 3 EXECUTIVE SUMMARY 58 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS 58 3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS 62 3.3 DISRUPTIVE TRENDS SHAPING GLP-1 AGONISTS MARKET 62 3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 63 4 PREMIUM INSIGHTS 64 4.1 GLOBAL GLP-1 AGONISTS MARKET SNAPSHOT 64 4.2 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION AND COUNTRY, 2024 65 4.3 GLP-1 AGONISTS MARKET, BY FORMAT, 2024 65 4.4 GLP-1 AGONISTS MARKET, BY END USER, 2024 66 4.5 GLP-1 AGONISTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 66 4.6 UNMET NEEDS & WHITE SPACES 67 4.7 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES 67 4.7.1 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES 67 4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS 68 4.9 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 68 4.10 GLP-1 AGONISTS PRODUCTION CAPACITY HIGHLIGHTS 69 4.11 KEY DRUG LAUNCHES EXPECTED, 2025–2033 69 4.12 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 70 5 MARKET OVERVIEW 71 5.1 INTRODUCTION 71 5.2 MARKET DYNAMICS 71 5.2.1 DRIVERS 72 5.2.1.1 Expanding manufacturing capacities of large pharmaceutical companies 72 5.2.1.2 Shift of GLP-1 drugs from diabetes specialty to broader treatment options 73 5.2.1.3 Rising prevalence of obesity and type-2 diabetes 74 5.2.2 RESTRAINTS 75 5.2.2.1 Stringent cost and payer controls 75 5.2.3 OPPORTUNITIES 76 5.2.3.1 Increasing studies on oral GLP-1 76 5.2.4 CHALLENGES 76 5.2.4.1 Counterfeits and compounded GLP-1 gray market 76 5.2.4.2 Safety, tolerability, and persistence issues 77 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 78 5.3.1 KEY GLP-1 AGONISTS PIPELINE & EXPECTED LAUNCHES 78 5.4 PRICING ANALYSIS 80 5.4.1 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024 80 5.4.2 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024 80 5.4.3 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY REGION, 2022–2024 81 5.4.4 FACTORS IMPACTING GLP-1 AGONISTS PRICING 83 5.5 INDUSTRY TRENDS 83 5.5.1 SHIFT OF WEEKLY INJECTABLES TOWARD ORALS AND MULTI-AGONISTS 83 5.5.2 VERTICAL INTEGRATION AND CAPACITY SCALE-UP TO MEET DEMAND 83 5.6 TECHNOLOGY ANALYSIS 84 5.6.1 KEY TECHNOLOGIES 84 5.6.1.1 Chemical synthesis 84 5.6.1.2 Recombinant DNA technology 85   5.6.2 COMPLEMENTARY TECHNOLOGIES 85 5.6.2.1 Peptelligence 85 5.6.2.2 PEGylation and polymer encapsulation 86 5.6.3 ADJACENT TECHNOLOGIES 86 5.6.3.1 Hydrogel depot technologies 86 5.6.3.2 Technologies for oral delivery of GLP-1 analogues 87 5.7 PIPELINE ANALYSIS 88 5.8 TECHNOLOGY/PRODUCT ROADMAP 92 5.9 VALUE CHAIN ANALYSIS 92 5.10 ECOSYSTEM ANALYSIS 93 5.10.1 ROLE IN ECOSYSTEM 94 5.11 PORTER’S FIVE FORCES ANALYSIS 95 5.11.1 THREAT OF NEW ENTRANTS 96 5.11.2 THREAT OF SUBSTITUTES 96 5.11.3 BARGAINING POWER OF SUPPLIERS 96 5.11.4 BARGAINING POWER OF BUYERS 96 5.11.5 INTENSITY OF COMPETITIVE RIVALRY 96 5.12 REGULATORY ANALYSIS 96 5.12.1 REGULATORY LANDSCAPE 96 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 5.13 KEY CONFERENCES & EVENTS, 2025–2026 100 5.14 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 101 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 101 5.14.2 KEY BUYING CRITERIA 102 5.14.3 ADOPTION BARRIER & INTERNAL FRICTION 103 5.15 INVESTMENT/FUNDING SCENARIO 104 5.16 REIMBURSEMENT SCENARIO 105 5.17 IMPACT OF AI/GEN AI ON GLP-1 AGONISTS MARKET 105 5.17.1 IMPACT AT DEVELOPMENT AND MANUFACTURING STAGES 105 5.17.2 AI USE CASES 106 5.17.3 KEY COMPANIES IMPLEMENTING AI 106 5.17.4 FUTURE OF AI/GEN AI IN GLP-1 AGONIST DRUG DEVELOPMENT ECOSYSTEM 107 5.18 IMPACT OF 2025 TRUMP TARIFF ON GLP-1 AGONISTS MARKET 107 5.18.1 INTRODUCTION 107 5.18.2 KEY TARIFF RATES 108 5.18.3 PRICE IMPACT ANALYSIS 108 5.18.4 IMPACT ON REGION 108 5.18.4.1 North America 108 5.18.4.2 Europe 109 5.18.4.3 Asia Pacific 109   5.18.5 IMPACT ON END-USE INDUSTRIES 110 5.18.5.1 Hospitals & specialty centers 110 5.18.5.2 Long-term care facilities 110 6 GLP-1 AGONISTS MARKET, BY PRODUCT 111 6.1 INTRODUCTION 112 6.2 GLP-1 AGONISTS VOLUME MARKET ESTIMATION 113 6.3 OZEMPIC 113 6.3.1 ANTICIPATED PATENT EXPIRY OF SEMAGLUTIDE STARTING IN 2026 AND EXPECTED NEW DRUG LAUNCHES TO NEGATIVELY IMPACT MARKET 113 6.4 TRULICITY 116 6.4.1 LOSS OF PATENT EXCLUSIVITY AND HIGH COMPETITIVE PRESSURE TO DISRUPT MARKET GROWTH 116 6.5 MOUNJARO 119 6.5.1 DUAL MECHANISM AS BOTH GIP AND GLP-1 RECEPTOR AGONIST TO PROPEL ADOPTION 119 6.6 WEGOVY 122 6.6.1 INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT MARKET GROWTH 122 6.7 RYBELSUS 125 6.7.1 EASE OF ADMINISTRATION TO FUEL ADOPTION AMONG PATIENTS 125 6.8 ZEPBOUND 128 6.8.1 INCREASED FOCUS ON OBESITY MANAGEMENT TO INDICATE HUGE GROWTH POTENTIAL 128 6.9 ORFORGLIPRON 131 6.9.1 ORFORGLIPRON TO GAIN HIGH POTENTIAL DUE TO DEVICE-FREE LOGISTICS AND NO FASTING WINDOW 131 6.10 CAGRISEMA 135 6.10.1 FOCUS ON CHRONIC WEIGHT MANAGEMENT AND TYPE 2 DIABETES TREATMENT TO SPUR MARKET GROWTH 135 6.11 SURVODUTIDE 138 6.11.1 STRONG CLINICAL EFFICACY IN OBESITY AND METABOLIC DISEASE MANAGEMENT TO AID MARKET GROWTH 138 6.12 RETATRUTIDE 142 6.12.1 STRONG WEIGHT-LOSS SIGNALS IN PHASE-2 DIABETES AND GLOBAL PHASE-3 CLINICAL PIPELINE TO DRIVE MARKET 142 6.13 SEMAGLUTIDE BIOSIMILARS 145 6.13.1 HIGH DEMAND FOR AFFORDABLE DIABETES AND OBESITY TREATMENTS TO AID GROWTH 145 6.14 OTHER GLP-1 BIOSIMILARS 149 6.15 OTHER PRODUCTS 152   7 GLP-1 AGONISTS MARKET, BY MOLECULE 155 7.1 INTRODUCTION 156 7.2 SEMAGLUTIDE 156 7.2.1 PROVEN EFFICACY IN SIGNIFICANT WEIGHT LOSS AND GLYCEMIC CONTROL TO SUPPORT GROWTH 156 7.3 TIRZEPATIDE 160 7.3.1 STRONG EFFECTIVENESS IN OBESITY TREATMENT TO ENHANCE PHYSICIAN CONFIDENCE AND PAYER INTEREST 160 7.4 DULAGLUTIDE 163 7.4.1 USAGE IN PEDIATRIC TYPE 2 DIABETES FOR PATIENTS OVER 10 YEARS OLD TO ENHANCE USAGE IN SPECIALTY SETTINGS 163 7.5 CAGRILINTIDE SEMAGLUTIDE COMBINATION 166 7.5.1 SIGNIFICANT CLINICAL OUTCOMES IN WEIGHT MANAGEMENT TO DRIVE MARKET GROWTH 166 7.6 ORFORGLIPRON 170 7.6.1 NEEDLE-FREE ALTERNATIVE TO INCREASE CONVENIENCE AND SUPPORT ADOPTION AMONG PATIENTS 170 7.7 SURVODUTIDE 173 7.7.1 DUAL GCG/GLP-1 RECEPTOR AGONISM AND FAVORABLE CLINICAL EVIDENCE TO AID GROWTH 173 7.8 RETATRUTIDE 177 7.8.1 TRIPLE-AGONIST APPROACH AND BEST-IN-CLASS WEIGHT MANAGEMENT FOR OBESITY TO SHOW HIGH GROWTH POTENTIAL 177 7.9 OTHER MOLECULES 180 8 GLP-1 AGONISTS MARKET, BY TYPE 184 8.1 INTRODUCTION 185 8.2 PATENTED PRODUCTS 185 8.2.1 PATENTED GLP-1 BRANDS TO SHIFT FROM WEIGHT LOSS DRUGS TO CARDIOMETABOLIC THERAPIES FOR BETTER ACCESS AND DURABILITY 185 8.3 BIOSIMILARS 189 8.3.1 SEMAGLUTIDE BIOSIMILARS 193 8.3.1.1 Upcoming patent expiry for major drugs in key markets to increase biosimilar adoption 193 8.3.2 OTHER BIOSIMILARS 197 9 GLP-1 AGONISTS MARKET, BY INDICATION 200 9.1 INTRODUCTIONS 201 9.2 DIABETES 201 9.2.1 HIGH DIABETES PREVALENCE TO FUEL MARKET ADOPTION 201 9.3 OBESITY 204 9.3.1 STRONG PIPELINE OF ANTI-OBESITY GLP-1 DRUGS TO DRIVE MARKET 204 9.4 OTHER INDICATIONS 207   10 GLP-1 AGONISTS MARKET, BY FORMAT 211 10.1 INTRODUCTION 212 10.2 SINGLE-DOSE FORMATS 212 10.2.1 EASE OF ADMINISTRATION, DOSING AMOUNT PRECISION, AND LOW CONTAMINATION RISK TO SUPPORT MARKET GROWTH 212 10.3 MULTI-DOSE FORMATS 216 10.3.1 COST-EFFECTIVENESS AND LOW MEDICAL WASTE GENERATION TO AUGMENT ADOPTION IN HEALTHCARE SETTINGS 216 10.4 AUTOINJECTORS 219 10.4.1 SIMPLIFIED INJECTION PROCESS WITH LOWER HUMAN ERRORS TO SUPPORT ADOPTION 219 11 GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION 223 11.1 INTRODUCTION 224 11.2 SUBCUTANEOUS ADMINISTRATION 224 11.2.1 PEN INJECTORS 228 11.2.1.1 Easy monitoring of volume and dosage strength to support adoption 228 11.2.2 AUTOINJECTORS 230 11.2.2.1 Simplified injection process with lower human errors to support adoption 230 11.3 ORAL ADMINISTRATION 233 11.3.1 ELIMINATION OF NEEDLEPHOBIA AND EASE OF USE TO DRIVE COMPLIANCE 233 12 GLP-1 AGONISTS MARKET, BY END USER 237 12.1 INTRODUCTION 238 12.2 HOME CARE SETTINGS AND FITNESS/ WEIGHT MANAGEMENT FACILITIES 238 12.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH 238 12.3 LONG-TERM CARE FACILITIES 242 12.3.1 GROWING GERIATRIC POPULATION WITH CHRONIC DISEASES TO SUPPORT SEGMENT GROWTH 242 12.4 HOSPITALS & SPECIALTY CLINICS 245 12.4.1 ORGANIZED ENVIRONMENT, PROFESSIONAL OVERSIGHT, AND ABILITY TO HANDLE COMPLEX PATIENT NEEDS TO DRIVE MARKET 245 13 GLP-1 AGONISTS MARKET, BY REGION 249 13.1 INTRODUCTION 250 13.2 NORTH AMERICA 251 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 255 13.2.2 US 256 13.2.2.1 US to dominate North American GLP-1 agonists market during forecast period 256   13.2.3 CANADA 260 13.2.3.1 Favorable funding scenario and presence of strong research infrastructure to support market growth 260 13.3 EUROPE 264 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 268 13.3.2 GERMANY 269 13.3.2.1 Expertise in biotechnology and reputation as leading pharmaceutical manufacturing hub to expedite market growth 269 13.3.3 UK 273 13.3.3.1 Growing R&D initiatives for development of GLP-1 agonists drugs to support market growth 273 13.3.4 FRANCE 277 13.3.4.1 Favorable regulatory scenario and strong research infrastructure to propel market growth 277 13.3.5 ITALY 281 13.3.5.1 Presence of key pharmaceutical & biotechnology companies to boost market growth 281 13.3.6 SPAIN 285 13.3.6.1 High incidence of diabetes and obesity to augment market adoption of GLP-1 therapeutic drugs 285 13.3.7 NETHERLANDS 289 13.3.7.1 Strong focus on pharmaceutical R&D to support market growth 289 13.3.8 REST OF EUROPE 293 13.4 ASIA PACIFIC 297 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 302 13.4.2 CHINA 303 13.4.2.1 Increasing endorsements of anti-obesity drugs by celebrities to drive market adoption 303 13.4.3 JAPAN 307 13.4.3.1 High diabetic population and favorable regulatory scenario to aid market growth 307 13.4.4 INDIA 311 13.4.4.1 Growing demand for cost-effective and accessible anti-obesity medications to aid market growth 311 13.4.5 AUSTRALIA 315 13.4.5.1 Significant government investment in obesity prevention to fuel market growth 315 13.4.6 SOUTH KOREA 319 13.4.6.1 Increasing strategic collaborations in obesity drugs to propel market growth 319 13.4.7 REST OF ASIA PACIFIC 323 13.5 LATIN AMERICA 327 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 331 13.5.2 BRAZIL 332 13.5.2.1 Increasing partnerships with global pharmaceutical companies and rising diabetes cases to drive Brazilian market 332 13.5.3 MEXICO 336 13.5.3.1 Growing diabetes and obesity prevalence to support market growth 336 13.5.4 REST OF LATIN AMERICA 340 13.6 MIDDLE EAST 344 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 348 13.6.2 GCC COUNTRIES 349 13.6.2.1 Kingdom of Saudi Arabia 353 13.6.2.1.1 Pricing oversight of Saudi Food and Drug Authority and strong sales from leading industry players to drive market 353 13.6.2.2 UAE 358 13.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to spur market growth 358 13.6.2.3 Rest of GCC Countries 362 13.6.3 REST OF MIDDLE EAST 366 13.7 AFRICA 370 13.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH 370 13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 374 14 COMPETITIVE LANDSCAPE 375 14.1 INTRODUCTION 375 14.2 KEY STRATEGIES/RIGHT TO WIN 375 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 AGONISTS MARKET 375 14.3 REVENUE ANALYSIS, 2020–2024 377 14.4 MARKET SHARE ANALYSIS, 2024 377 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 379 14.5.1 STARS 379 14.5.2 EMERGING LEADERS 379 14.5.3 PERVASIVE PLAYERS 379 14.5.4 PARTICIPANTS 380 14.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (WITH PRODUCTS IN PIPELINE), 2024 381 14.6.1 STARS 381 14.6.2 EMERGING LEADERS 381 14.6.3 PERVASIVE PLAYERS 381 14.6.4 PARTICIPANTS 381 14.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 383 14.6.5.1 Company footprint 383 14.6.5.2 Region footprint 384 14.6.5.3 Format footprint 385 14.6.5.4 Route of administration footprint 385 14.6.5.5 Indication footprint 386   14.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 387 14.7.1 PROGRESSIVE COMPANIES 387 14.7.2 RESPONSIVE COMPANIES 387 14.7.3 DYNAMIC COMPANIES 387 14.7.4 STARTING BLOCKS 387 14.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 389 14.7.5.1 Competitive benchmarking of key startups/SMEs 390 14.8 COMPANY VALUATION & FINANCIAL METRICS 391 14.8.1 FINANCIAL METRICS 391 14.8.2 COMPANY VALUATION 391 14.9 BRAND/PRODUCT COMPARISON 392 14.10 COMPETITIVE SCENARIO 392 14.10.1 PRODUCT APPROVALS 392 14.10.2 DEALS 393 14.10.3 EXPANSIONS 394 14.10.4 OTHER DEVELOPMENTS 395 15 COMPANY PROFILES 396 15.1 INTRODUCTION 396 15.2 KEY PLAYERS 396 15.2.1 NOVO NORDISK A/S 396 15.2.1.1 Business overview 396 15.2.1.2 Products offered 397 15.2.1.3 Recent developments 398 15.2.1.3.1 Product approvals 398 15.2.1.3.2 Deals 399 15.2.1.3.3 Expansions 400 15.2.1.3.4 Other developments 400 15.2.1.4 MnM view 400 15.2.1.4.1 Right to win 400 15.2.1.4.2 Strategic choices 401 15.2.1.4.3 Weaknesses & competitive threats 401 15.2.2 ELI LILLY AND COMPANY 402 15.2.2.1 Business overview 402 15.2.2.2 Products offered 403 15.2.2.3 Recent developments 404 15.2.2.3.1 Product approvals 404 15.2.2.3.2 Deals 404 15.2.2.3.3 Expansions 405 15.2.2.4 MnM view 406 15.2.2.4.1 Right to win 406 15.2.2.4.2 Strategic choices 406 15.2.2.4.3 Weaknesses & competitive threats 406 15.2.3 SANOFI 407 15.2.3.1 Business overview 407 15.2.3.2 Products offered 408 15.2.3.3 MnM view 408 15.2.3.3.1 Key strengths 408 15.2.3.3.2 Strategic choices 408 15.2.3.3.3 Weaknesses & competitive threats 408 15.2.4 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED 409 15.2.4.1 Business overview 409 15.2.4.2 Products offered 410 15.2.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 411 15.2.5.1 Business overview 411 15.2.5.2 Products offered (in pipeline) 412 15.2.5.3 Recent developments 413 15.2.5.3.1 Other developments 413 15.2.6 INNOVENT 414 15.2.6.1 Business overview 414 15.2.6.2 Products offered (in pipeline) 415 15.2.6.3 Recent developments 415 15.2.6.3.1 Product approvals 415 15.2.6.3.2 Other developments 416 15.2.7 PEGBIO CO., LTD. 417 15.2.7.1 Business overview 417 15.2.7.2 Products offered (in pipeline) 417 15.2.8 SCIWIND BIOSCIENCES CO., LTD. 418 15.2.8.1 Business overview 418 15.2.8.2 Products offered (in pipeline) 418 15.2.8.3 Recent developments 419 15.2.8.3.1 Deals 419 15.2.8.3.2 Other developments 419 15.2.9 ZEALAND PHARMA 420 15.2.9.1 Business overview 420 15.2.9.2 Products offered (in pipeline) 421 15.2.9.3 Recent developments 421 15.2.9.3.1 Deals 421 15.2.9.3.2 Other developments 421 15.2.10 STRUCTURE THERAPEUTICS, INC. 422 15.2.10.1 Business overview 422 15.2.10.2 Products offered (in pipeline) 422 15.2.10.3 Recent developments 422 15.2.10.3.1 Other developments 422 15.2.11 VIKING THERAPEUTICS 423 15.2.11.1 Business overview 423 15.2.11.2 Products offered (in pipeline) 423 15.2.11.3 Recent developments 424 15.2.11.3.1 Deals 424 15.2.12 SUN PHARMACEUTICAL INDUSTRIES LTD. 425 15.2.12.1 Business overview 425 15.2.12.2 Products offered (in pipeline) 426 15.2.13 VTV THERAPEUTICS 427 15.2.13.1 Business overview 427 15.2.13.2 Products offered (in pipeline) 427 15.2.14 ALTIMMUNE 428 15.2.14.1 Business overview 428 15.2.14.2 Products offered (in pipeline) 428 15.2.14.3 Recent developments 429 15.2.14.3.1 Other developments 429 15.2.15 AMGEN INC. 430 15.2.15.1 Business overview 430 15.2.15.2 Products offered (in pipeline) 431 15.2.16 GLENMARK PHARMACEUTICALS LTD. 432 15.2.16.1 Business overview 432 15.2.16.2 Products offered (in pipeline) 433 15.2.16.3 Recent developments 433 15.2.16.3.1 Product launches 433 15.2.17 BIOCON 434 15.2.17.1 Business overview 434 15.2.17.2 Products offered (in pipeline) 435 15.2.17.3 Recent developments 436 15.2.17.3.1 Product launches and approvals 436 15.2.17.3.2 Deals 436 15.2.18 TEVA PHARMACEUTICAL INDUSTRIES LTD. 438 15.2.18.1 Business overview 438 15.2.18.2 Products offered (in pipeline) 439 15.2.18.3 Recent developments 439 15.2.18.3.1 Product launches 439 15.2.19 F. HOFFMANN-LA ROCHE LTD. 440 15.2.19.1 Business overview 440 15.2.19.2 Products offered (in pipeline) 441 15.2.19.3 Recent developments 442 15.2.19.3.1 Deals 442   15.3 OTHER PLAYERS 443 15.3.1 TERNS PHARMACEUTICALS, INC. 443 15.3.2 METAVIA 443 15.3.3 SCOHIA PHARMA, INC. 444 15.3.4 REGOR THERAPEUTICS GROUP 444 15.3.5 NEURALY INC. 445 15.3.6 I2O THERAPEUTICS, INC. 445 15.3.7 PFIZER INC. 446 15.3.8 HANMI PHARM CO.,LTD. 446 15.3.9 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 447 15.3.10 BIOMED INDUSTRIES, INC. 447 16 APPENDIX 448 16.1 DISCUSSION GUIDE 448 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 452 16.3 CUSTOMIZATION OPTIONS 454 16.4 RELATED REPORTS 454 16.5 AUTHOR DETAILS 455
圖表清單 List of Tables & Figures
TABLE 1 GLP-1 AGONISTS MARKET: INCLUSIONS & EXCLUSIONS 44 TABLE 2 GLP-1 AGONISTS MARKET: RISK ANALYSIS 57 TABLE 3 GLP-1 AGONISTS MARKET: STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES 67 TABLE 4 GLP-1 AGONISTS MARKET: EMERGING BUSINESS MODELS & TARGET SEGMENTS 68 TABLE 5 EXPECTED KEY LAUNCHES IN GLP-1 AGONISTS MARKET, 2025–2033 69 TABLE 6 GLP-1 AGONISTS MARKET: IMPACT ANALYSIS 72 TABLE 7 KEY GLP-1 AGONISTS PIPELINE & EXPECTED LAUNCHES 78 TABLE 8 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 80 TABLE 9 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY REGION, 2022–2024 (USD) 81 TABLE 10 GLP-1 AGONISTS IN CLINICAL PIPELINE (AS OF SEPTEMBER 2025) 88 TABLE 11 GLP-1 AGONISTS MARKET: ROLE IN ECOSYSTEM 94 TABLE 12 GLP-1 AGONISTS MARKET: PORTER’S FIVE FORCES 95 TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99 TABLE 17 LIST OF KEY CONFERENCES & EVENTS IN GLP-1 AGONISTS MARKET, JANUARY 2025–DECEMBER 2026 100 TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 101 TABLE 19 BUYING CRITERIA FOR GLP-1 AGONIST PRODUCTS, BY END USER 102 TABLE 20 GLP-1 AGONISTS: ADOPTION BARRIER & INTERNAL FRICTION 103 TABLE 21 KEY COMPANIES IMPLEMENTING AI IN GLP-1 AGONISTS MARKET 106 TABLE 22 GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 112 TABLE 23 GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (MILLION UNITS) 113 TABLE 24 GLP-1 AGONISTS MARKET FOR OZEMPIC, BY REGION, 2024–2033 (USD BILLION) 113 TABLE 25 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION) 114 TABLE 26 EUROPE: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION) 114 TABLE 27 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION) 115 TABLE 28 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION) 115 TABLE 29 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY REGION, 2024–2033 (USD BILLION) 115 TABLE 30 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION) 116 TABLE 31 GLP-1 AGONISTS MARKET FOR TRULICITY, BY REGION, 2024–2033 (USD BILLION) 116 TABLE 32 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024–2033 (USD BILLION) 117 TABLE 33 EUROPE: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024–2033 (USD BILLION) 117 TABLE 34 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024–2033 (USD BILLION) 118 TABLE 35 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024–2033 (USD BILLION) 118 TABLE 36 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TRULICITY, BY REGION, 2024–2033 (USD BILLION) 118 TABLE 37 GLP-1 AGONISTS MARKET FOR MOUNJARO, BY REGION, 2024–2033 (USD BILLION) 119 TABLE 38 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION) 120 TABLE 39 EUROPE: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION) 120 TABLE 40 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION) 121 TABLE 41 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION) 121 TABLE 42 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY REGION, 2024–2033 (USD BILLION) 121 TABLE 43 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION) 122 TABLE 44 GLP-1 AGONISTS MARKET FOR WEGOVY, BY REGION, 2024–2033 (USD BILLION) 122 TABLE 45 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION) 123 TABLE 46 EUROPE: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION) 123 TABLE 47 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION) 124 TABLE 48 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION) 124 TABLE 49 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR WEGOVY, BY REGION, 2024–2033 (USD BILLION) 124 TABLE 50 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION) 125 TABLE 51 GLP-1 AGONISTS MARKET FOR RYBELSUS, BY REGION, 2024–2033 (USD BILLION) 125 TABLE 52 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION) 126 TABLE 53 EUROPE: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION) 126 TABLE 54 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION) 127 TABLE 55 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION) 127 TABLE 56 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY REGION, 2024–2033 (USD BILLION) 127 TABLE 57 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION) 128 TABLE 58 GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY REGION, 2024–2033 (USD BILLION) 128 TABLE 59 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, S2024–2033 (USD BILLION) 129 TABLE 60 EUROPE: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024–2033 (USD BILLION) 129 TABLE 61 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024–2033 (USD BILLION) 130 TABLE 62 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024–2033 (USD BILLION) 130 TABLE 63 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY REGION, 2024–2033 (USD BILLION) 131 TABLE 64 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024–2033 (USD BILLION) 131 TABLE 65 GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024–2033 (USD BILLION) 132 TABLE 66 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION) 132 TABLE 67 EUROPE: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION) 133 TABLE 68 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION) 133 TABLE 69 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION) 134 TABLE 70 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024–2033 (USD BILLION) 134 TABLE 71 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION) 134 TABLE 72 GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY REGION, 2024–2033 (USD BILLION) 135 TABLE 73 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION) 136 TABLE 74 EUROPE: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION) 136 TABLE 75 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION) 137 TABLE 76 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION) 137 TABLE 77 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY REGION, 2024–2033 (USD BILLION) 138 TABLE 78 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION) 138 TABLE 79 GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024–2033 (USD BILLION) 139 TABLE 80 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 139 TABLE 81 EUROPE: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 140 TABLE 82 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 140 TABLE 83 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 141 TABLE 84 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024–2033 (USD BILLION) 141 TABLE 85 GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024–2033 (USD BILLION) 142 TABLE 86 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 143 TABLE 87 EUROPE: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 143 TABLE 88 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 144 TABLE 89 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 144 TABLE 90 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024–2033 (USD BILLION) 145 TABLE 91 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 145 TABLE 92 GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION) 146 TABLE 93 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 146 TABLE 94 EUROPE: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 147 TABLE 95 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 147 TABLE 96 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 148 TABLE 97 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION) 148 TABLE 98 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 148 TABLE 99 GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION) 149 TABLE 100 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 149 TABLE 101 EUROPE: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 150 TABLE 102 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 150 TABLE 103 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 151 TABLE 104 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION) 151 TABLE 105 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 151 TABLE 106 GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2033 (USD BILLION) 152 TABLE 107 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION) 152 TABLE 108 EUROPE: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION) 153 TABLE 109 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION) 153 TABLE 110 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION) 154 TABLE 111 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2033 (USD BILLION) 154 TABLE 112 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION) 154 TABLE 113 GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 156 TABLE 114 GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY REGION, 2024–2033 (USD BILLION) 157 TABLE 115 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 157 TABLE 116 EUROPE: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 158 TABLE 117 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 158 TABLE 118 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 159 TABLE 119 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY REGION, 2024–2033 (USD BILLION) 159 TABLE 120 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 159 TABLE 121 GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY REGION, 2024–2033 (USD BILLION) 160 TABLE 122 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION) 161 TABLE 123 EUROPE: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION) 161 TABLE 124 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION) 162 TABLE 125 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION) 162 TABLE 126 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY REGION, 2024–2033 (USD BILLION) 162 TABLE 127 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION) 163 TABLE 128 GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY REGION, 2024–2033 (USD BILLION) 163 TABLE 129 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 164 TABLE 130 EUROPE: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 164 TABLE 131 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 165 TABLE 132 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 165 TABLE 133 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY REGION, 2024–2033 (USD BILLION) 165 TABLE 134 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 166 TABLE 135 GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY REGION, 2024–2033 (USD BILLION) 167 TABLE 136 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION) 167 TABLE 137 EUROPE: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION) 168 TABLE 138 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION) 168 TABLE 139 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION) 169 TABLE 140 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY REGION, 2024–2033 (USD BILLION) 169 TABLE 141 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION) 169 TABLE 142 GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024–2033 (USD BILLION) 170 TABLE 143 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION) 171 TABLE 144 EUROPE: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION) 171 TABLE 145 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION) 172 TABLE 146 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION) 172 TABLE 147 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024–2033 (USD BILLION) 172 TABLE 148 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION) 173 TABLE 149 GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024–2033 (USD BILLION) 174 TABLE 150 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 174 TABLE 151 EUROPE: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 175 TABLE 152 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 175 TABLE 153 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 176 TABLE 154 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024–2033 (USD BILLION) 176 TABLE 155 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 176 TABLE 156 GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024–2033 (USD BILLION) 177 TABLE 157 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 178 TABLE 158 EUROPE: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 178 TABLE 159 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 179 TABLE 160 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 179 TABLE 161 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024–2033 (USD BILLION) 180 TABLE 162 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION) 180 TABLE 163 GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY REGION, 2024–2033 (USD BILLION) 181 TABLE 164 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION) 181 TABLE 165 EUROPE: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION) 182 TABLE 166 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION) 182 TABLE 167 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION) 183 TABLE 168 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY REGION, 2024–2033 (USD BILLION) 183 TABLE 169 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION) 183 TABLE 170 GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 185 TABLE 171 GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY REGION, 2024–2033 (USD BILLION) 186 TABLE 172 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION) 186 TABLE 173 EUROPE: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION) 187 TABLE 174 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION) 187 TABLE 175 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION) 188 TABLE 176 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY REGION, 2024–2033 (USD BILLION) 188 TABLE 177 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION) 188 TABLE 178 GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION) 189 TABLE 179 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 190 TABLE 180 EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 190 TABLE 181 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 191 TABLE 182 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 191 TABLE 183 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION) 192 TABLE 184 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION) 192 TABLE 185 GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 192 TABLE 186 SEMAGLUTIDE BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION) 194 TABLE 187 NORTH AMERICA: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 194 TABLE 188 EUROPE: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 195 TABLE 189 ASIA PACIFIC: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 195 TABLE 190 LATIN AMERICA: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 196 TABLE 191 MIDDLE EAST: SEMAGLUTIDE BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION) 196 TABLE 192 GCC COUNTRIES: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 196 TABLE 193 OTHER BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION) 197 TABLE 194 NORTH AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 197 TABLE 195 EUROPE: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 198 TABLE 196 ASIA PACIFIC: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 198 TABLE 197 LATIN AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 199 TABLE 198 MIDDLE EAST: OTHER BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION) 199 TABLE 199 GCC COUNTRIES: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 199 TABLE 200 GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 201 TABLE 201 GLP-1 AGONISTS MARKET FOR DIABETES, BY REGION, 2024–2033 (USD BILLION) 202 TABLE 202 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION) 202 TABLE 203 EUROPE: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION) 202 TABLE 204 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION) 203 TABLE 205 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION) 203 TABLE 206 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR DIABETES, BY REGION, 2024–2033 (USD BILLION) 203 TABLE 207 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION) 204 TABLE 208 GLP-1 AGONISTS MARKET FOR OBESITY, BY REGION, 2024–2033 (USD BILLION) 205 TABLE 209 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION) 205 TABLE 210 EUROPE: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION) 205 TABLE 211 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION) 206 TABLE 212 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION) 206 TABLE 213 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OBESITY, BY REGION, 2024–2033 (USD BILLION) 206 TABLE 214 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION) 207 TABLE 215 GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2033 (USD BILLION) 208 TABLE 216 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION) 208 TABLE 217 EUROPE: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION) 209 TABLE 218 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION) 209 TABLE 219 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION) 210 TABLE 220 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2033 (USD BILLION) 210 TABLE 221 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION) 210 TABLE 222 GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 212 TABLE 223 GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY REGION, 2024–2033 (USD BILLION) 213 TABLE 224 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION) 213 TABLE 225 EUROPE: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION) 214 TABLE 226 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION) 214 TABLE 227 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION) 215 TABLE 228 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY REGION, 2024–2033 (USD BILLION) 215 TABLE 229 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION) 215 TABLE 230 GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY REGION, 2024–2033 (USD BILLION) 216 TABLE 231 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION) 217 TABLE 232 EUROPE: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION) 217 TABLE 233 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION) 218 TABLE 234 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION) 218 TABLE 235 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY REGION, 2024–2033 (USD BILLION) 218 TABLE 236 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION) 219 TABLE 237 GLP-1 AGONISTS MARKET FOR TABLETS, BY REGION, 2024–2033 (USD BILLION) 220 TABLE 238 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION) 220 TABLE 239 EUROPE: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION) 220 TABLE 240 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION) 221 TABLE 241 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION) 221 TABLE 242 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TABLETS, BY REGION, 2024–2033 (USD BILLION) 221 TABLE 243 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION) 222 TABLE 244 GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 224 TABLE 245 GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 225 TABLE 246 GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION) 225 TABLE 247 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION) 225 TABLE 248 EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION) 226 TABLE 249 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION) 226 TABLE 250 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION) 227 TABLE 251 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION) 227 TABLE 252 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION) 227 TABLE 253 PEN INJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION) 228 TABLE 254 NORTH AMERICA: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 228 TABLE 255 EUROPE: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 229 TABLE 256 ASIA PACIFIC: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 229 TABLE 257 LATIN AMERICA: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 229 TABLE 258 MIDDLE EAST: PEN INJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION) 230 TABLE 259 GCC COUNTRIES: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 230 TABLE 260 AUTOINJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION) 231 TABLE 261 NORTH AMERICA: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 231 TABLE 262 EUROPE: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 232 TABLE 263 ASIA PACIFIC: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 232 TABLE 264 LATIN AMERICA: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 232 TABLE 265 MIDDLE EAST: AUTOINJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION) 233 TABLE 266 GCC COUNTRIES: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 233 TABLE 267 GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION) 234 TABLE 268 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION) 234 TABLE 269 EUROPE: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION) 235 TABLE 270 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION) 235 TABLE 271 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION) 236 TABLE 272 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION) 236 TABLE 273 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION) 236 TABLE 274 GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 238 TABLE 275 GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY REGION, 2024–2033 (USD BILLION) 239 TABLE 276 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION) 239 TABLE 277 EUROPE: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION) 240 TABLE 278 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION) 240 TABLE 279 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION) 241 TABLE 280 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY REGION, 2024–2033 (USD BILLION) 241 TABLE 281 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION) 241 TABLE 282 GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2024–2033 (USD BILLION) 242 TABLE 283 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION) 243 TABLE 284 EUROPE: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION) 243 TABLE 285 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION) 244 TABLE 286 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION) 244 TABLE 287 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2024–2033 (USD BILLION) 244 TABLE 288 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION) 245 TABLE 289 GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024–2033 (USD BILLION) 246 TABLE 290 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION) 246 TABLE 291 EUROPE: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION) 247 TABLE 292 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION) 247 TABLE 293 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION) 248 TABLE 294 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024–2033 (USD BILLION) 248 TABLE 295 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION) 248 TABLE 296 GLP-1 AGONISTS MARKET, BY REGION, 2024–2033 (USD BILLION) 250 TABLE 297 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 252 TABLE 298 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 252 TABLE 299 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 253 TABLE 300 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 253 TABLE 301 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 253 TABLE 302 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 254 TABLE 303 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 254 TABLE 304 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 254 TABLE 305 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 255 TABLE 306 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 255 TABLE 307 NORTH AMERICA: KEY MACROINDICATORS 256 TABLE 308 US: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 257 TABLE 309 US: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 258 TABLE 310 US: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 258 TABLE 311 US: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 258 TABLE 312 US: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 259 TABLE 313 US: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 259 TABLE 314 US: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 259 TABLE 315 US: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 260 TABLE 316 US: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 260 TABLE 317 CANADA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 261 TABLE 318 CANADA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 261 TABLE 319 CANADA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 262 TABLE 320 CANADA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 262 TABLE 321 CANADA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 262 TABLE 322 CANADA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 263 TABLE 323 CANADA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 263 TABLE 324 CANADA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 263 TABLE 325 CANADA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 264 TABLE 326 EUROPE: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 264 TABLE 327 EUROPE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 265 TABLE 328 EUROPE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 265 TABLE 329 EUROPE: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 266 TABLE 330 EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 266 TABLE 331 EUROPE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 266 TABLE 332 EUROPE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 267 TABLE 333 EUROPE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 267 TABLE 334 EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 267 TABLE 335 EUROPE: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 268 TABLE 336 EUROPE: KEY MACROINDICATORS 269 TABLE 337 GERMANY: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 270 TABLE 338 GERMANY: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 270 TABLE 339 GERMANY: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 271 TABLE 340 GERMANY: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 271 TABLE 341 GERMANY: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 271 TABLE 342 GERMANY: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 272 TABLE 343 GERMANY: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 272 TABLE 344 GERMANY: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 272 TABLE 345 GERMANY: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 273 TABLE 346 UK: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 274 TABLE 347 UK: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 274 TABLE 348 UK: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 275 TABLE 349 UK: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 275 TABLE 350 UK: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 275 TABLE 351 UK: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 276 TABLE 352 UK: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 276 TABLE 353 UK: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 276 TABLE 354 UK: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 277 TABLE 355 FRANCE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 278 TABLE 356 FRANCE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 278 TABLE 357 FRANCE: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 279 TABLE 358 FRANCE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 279 TABLE 359 FRANCE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 279 TABLE 360 FRANCE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 280 TABLE 361 FRANCE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 280 TABLE 362 FRANCE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 280 TABLE 363 FRANCE: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 281 TABLE 364 ITALY: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 282 TABLE 365 ITALY: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 282 TABLE 366 ITALY: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 283 TABLE 367 ITALY: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 283 TABLE 368 ITALY: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 283 TABLE 369 ITALY: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 284 TABLE 370 ITALY: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 284 TABLE 371 ITALY: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 284 TABLE 372 ITALY: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 285 TABLE 373 SPAIN: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 286 TABLE 374 SPAIN: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 286 TABLE 375 SPAIN: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 287 TABLE 376 SPAIN: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 287 TABLE 377 SPAIN: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 287 TABLE 378 SPAIN: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 288 TABLE 379 SPAIN: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 288 TABLE 380 SPAIN: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 288 TABLE 381 SPAIN: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 289 TABLE 382 NETHERLANDS: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 290 TABLE 383 NETHERLANDS: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 290 TABLE 384 NETHERLANDS: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 291 TABLE 385 NETHERLANDS: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 291 TABLE 386 NETHERLANDS: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 291 TABLE 387 NETHERLANDS: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 292 TABLE 388 NETHERLANDS: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 292 TABLE 389 NETHERLANDS: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 292 TABLE 390 NETHERLANDS: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 293 TABLE 391 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 294 TABLE 392 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 294 TABLE 393 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 295 TABLE 394 REST OF EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 295 TABLE 395 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 295 TABLE 396 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 296 TABLE 397 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 296 TABLE 398 REST OF EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 296 TABLE 399 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 297 TABLE 400 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 298 TABLE 401 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 299 TABLE 402 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 299 TABLE 403 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 300 TABLE 404 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 300 TABLE 405 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 300 TABLE 406 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 301 TABLE 407 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 301 TABLE 408 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 301 TABLE 409 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 302 TABLE 410 ASIA PACIFIC: KEY MACROINDICATORS 303 TABLE 411 CHINA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 304 TABLE 412 CHINA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 305 TABLE 413 CHINA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 305 TABLE 414 CHINA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 305 TABLE 415 CHINA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 306 TABLE 416 CHINA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 306 TABLE 417 CHINA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 306 TABLE 418 CHINA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 307 TABLE 419 CHINA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 307 TABLE 420 JAPAN: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 308 TABLE 421 JAPAN: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 308 TABLE 422 JAPAN: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 309 TABLE 423 JAPAN: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 309 TABLE 424 JAPAN: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 309 TABLE 425 JAPAN: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 310 TABLE 426 JAPAN: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 310 TABLE 427 JAPAN: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 310 TABLE 428 JAPAN: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 311 TABLE 429 INDIA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 312 TABLE 430 INDIA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 312 TABLE 431 INDIA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 313 TABLE 432 INDIA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 313 TABLE 433 INDIA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 313 TABLE 434 INDIA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 314 TABLE 435 INDIA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 314 TABLE 436 INDIA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 314 TABLE 437 INDIA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 315 TABLE 438 AUSTRALIA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 316 TABLE 439 AUSTRALIA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 316 TABLE 440 AUSTRALIA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 317 TABLE 441 AUSTRALIA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 317 TABLE 442 AUSTRALIA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 317 TABLE 443 AUSTRALIA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 318 TABLE 444 AUSTRALIA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 318 TABLE 445 AUSTRALIA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 318 TABLE 446 AUSTRALIA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 319 TABLE 447 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 320 TABLE 448 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 320 TABLE 449 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 321 TABLE 450 SOUTH KOREA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 321 TABLE 451 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 321 TABLE 452 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 322 TABLE 453 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 322 TABLE 454 SOUTH KOREA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 322 TABLE 455 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 323 TABLE 456 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 324 TABLE 457 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 324 TABLE 458 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 325 TABLE 459 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 325 TABLE 460 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 325 TABLE 461 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 326 TABLE 462 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 326 TABLE 463 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 326 TABLE 464 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 327 TABLE 465 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 327 TABLE 466 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 328 TABLE 467 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 328 TABLE 468 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 329 TABLE 469 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 329 TABLE 470 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 329 TABLE 471 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 330 TABLE 472 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 330 TABLE 473 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 330 TABLE 474 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 331 TABLE 475 LATIN AMERICA: KEY MACROINDICATORS 332 TABLE 476 BRAZIL: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 333 TABLE 477 BRAZIL: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 333 TABLE 478 BRAZIL: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 334 TABLE 479 BRAZIL: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 334 TABLE 480 BRAZIL: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 334 TABLE 481 BRAZIL: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 335 TABLE 482 BRAZIL: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 335 TABLE 483 BRAZIL: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 335 TABLE 484 BRAZIL: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 336 TABLE 485 MEXICO: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 337 TABLE 486 MEXICO: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 337 TABLE 487 MEXICO: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 338 TABLE 488 MEXICO: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 338 TABLE 489 MEXICO: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 338 TABLE 490 MEXICO: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 339 TABLE 491 MEXICO: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 339 TABLE 492 MEXICO: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 339 TABLE 493 MEXICO: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 340 TABLE 494 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 340 TABLE 495 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 341 TABLE 496 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 341 TABLE 497 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 342 TABLE 498 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 342 TABLE 499 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 342 TABLE 500 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 343 TABLE 501 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 343 TABLE 502 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 343 TABLE 503 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 344 TABLE 504 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 345 TABLE 505 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 345 TABLE 506 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 346 TABLE 507 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 346 TABLE 508 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 346 TABLE 509 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 347 TABLE 510 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 347 TABLE 511 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 347 TABLE 512 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY REGION, 2024–2033 (USD BILLION) 348 TABLE 513 MIDDLE EAST: KEY MACROINDICATORS 349 TABLE 514 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 349 TABLE 515 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 350 TABLE 516 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 350 TABLE 517 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 351 TABLE 518 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 351 TABLE 519 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 351 TABLE 520 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 352 TABLE 521 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 352 TABLE 522 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 352 TABLE 523 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION) 353 TABLE 524 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 354 TABLE 525 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 355 TABLE 526 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 355 TABLE 527 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 356 TABLE 528 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 356 TABLE 529 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 356 TABLE 530 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 357 TABLE 531 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 357 TABLE 532 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 357 TABLE 533 UAE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 358 TABLE 534 UAE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 359 TABLE 535 UAE: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 359 TABLE 536 UAE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 359 TABLE 537 UAE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 360 TABLE 538 UAE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 360 TABLE 539 UAE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 360 TABLE 540 UAE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 361 TABLE 541 UAE: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 361 TABLE 542 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 362 TABLE 543 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 363 TABLE 544 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 363 TABLE 545 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 364 TABLE 546 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 364 TABLE 547 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 364 TABLE 548 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 365 TABLE 549 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 365 TABLE 550 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 365 TABLE 551 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 366 TABLE 552 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 367 TABLE 553 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 367 TABLE 554 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 368 TABLE 555 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 368 TABLE 556 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 368 TABLE 557 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 369 TABLE 558 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 369 TABLE 559 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 369 TABLE 560 AFRICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION) 370 TABLE 561 AFRICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION) 371 TABLE 562 AFRICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 371 TABLE 563 AFRICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION) 372 TABLE 564 AFRICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 372 TABLE 565 AFRICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION) 372 TABLE 566 AFRICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION) 373 TABLE 567 AFRICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 373 TABLE 568 AFRICA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 373 TABLE 569 AFRICA: KEY MACROINDICATORS 374 TABLE 570 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN GLP-1 AGONISTS MARKET 375 TABLE 571 GLP-1 AGONISTS MARKET: DEGREE OF COMPETITION 378 TABLE 572 GLP-1 AGONISTS MARKET: REGION FOOTPRINT (KEY PLAYERS) 384 TABLE 573 GLP-1 AGONISTS MARKET: REGION FOOTPRINT (PRODUCTS IN PIPELINE) 384 TABLE 574 GLP-1 AGONISTS MARKET: FORMAT FOOTPRINT 385 TABLE 575 GLP-1 AGONISTS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 385 TABLE 576 GLP-1 AGONISTS MARKET: INDICATION FOOTPRINT (KEY PLAYERS) 386 TABLE 577 GLP-1 AGONISTS MARKET: INDICATION FOOTPRINT (PRODUCTS IN PIPELINE) 386 TABLE 578 GLP-1 AGONISTS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 389 TABLE 579 GLP-1 AGONISTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY INDICATION AND REGION 390 TABLE 580 GLP-1 AGONISTS MARKET: PRODUCT APPROVALS, JANUARY 2022–SEPTEMBER 2025 392 TABLE 581 GLP-1 AGONISTS MARKET: DEALS, JANUARY 2022–SEPTEMBER 2025 393 TABLE 582 GLP-1 AGONISTS MARKET: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 394 TABLE 583 GLP-1 AGONISTS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 395 TABLE 584 NOVO NORDISK A/S: COMPANY OVERVIEW 396 TABLE 585 NOVO NORDISK A/S: PRODUCTS OFFERED 397 TABLE 586 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2022–SEPTEMBER 2025 398 TABLE 587 NOVO NORDISK A/S: DEALS, JANUARY 2022–SEPTEMBER 2025 399 TABLE 588 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 400 TABLE 589 NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 400 TABLE 590 ELI LILLY AND COMPANY: COMPANY OVERVIEW 402 TABLE 591 ELI LILLY AND COMPANY: PRODUCTS OFFERED 403 TABLE 592 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2022–SEPTEMBER 2025 404 TABLE 593 ELI LILLY AND COMPANY: DEALS, JANUARY 2022–SEPTEMBER 2025 404 TABLE 594 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 405 TABLE 595 SANOFI: COMPANY OVERVIEW 407 TABLE 596 SANOFI: PRODUCTS OFFERED 408 TABLE 597 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: COMPANY OVERVIEW 409 TABLE 598 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: PRODUCTS OFFERED 410 TABLE 599 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 411 TABLE 600 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED (IN PIPELINE) 412 TABLE 601 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 413 TABLE 602 INNOVENT: COMPANY OVERVIEW 414 TABLE 603 INNOVENT: PRODUCTS OFFERED (IN PIPELINE) 415 TABLE 604 INNOVENT: PRODUCT APPROVALS, JANUARY 2022–SEPTEMBER 2025 415 TABLE 605 INNOVENT: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 416 TABLE 606 PEGBIO CO., LTD.: COMPANY OVERVIEW 417 TABLE 607 PEGBIO CO., LTD.: PRODUCTS OFFERED (IN PIPELINE) 417 TABLE 608 SCIWIND BIOSCIENCES CO., LTD.: COMPANY OVERVIEW 418 TABLE 609 SCIWIND BIOSCIENCES CO., LTD.: PRODUCTS OFFERED (IN PIPELINE) 418 TABLE 610 SCIWIND BIOSCIENCES CO., LTD.: DEALS, JANUARY 2022–SEPTEMBER 2025 419   TABLE 611 SCIWIND BIOSCIENCES CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 419 TABLE 612 ZEALAND PHARMA: COMPANY OVERVIEW 420 TABLE 613 ZEALAND PHARMA: PRODUCTS OFFERED (IN PIPELINE) 421 TABLE 614 ZEALAND PHARMA: DEALS, JANUARY 2022–SEPTEMBER 2025 421 TABLE 615 ZEALAND PHARMA: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 421 TABLE 616 STRUCTURE THERAPEUTICS, INC.: COMPANY OVERVIEW 422 TABLE 617 STRUCTURE THERAPEUTICS, INC.: PRODUCTS OFFERED (IN PIPELINE) 422 TABLE 618 STRUCTURE THERAPEUTICS, INC.: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 422 TABLE 619 VIKING THERAPEUTICS: COMPANY OVERVIEW 423 TABLE 620 VIKING THERAPEUTICS: PRODUCTS OFFERED (IN PIPELINE) 423 TABLE 621 VIKING THERAPEUTICS: DEALS, JANUARY 2022–SEPTEMBER 2025 424 TABLE 622 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 425 TABLE 623 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED (IN PIPELINE) 426 TABLE 624 VTV THERAPEUTICS: COMPANY OVERVIEW 427 TABLE 625 VTV THERAPEUTICS: PRODUCTS OFFERED (IN PIPELINE) 427 TABLE 626 ALTIMMUNE: COMPANY OVERVIEW 428 TABLE 627 ALTIMMUNE: PRODUCTS OFFERED (IN PIPELINE) 428 TABLE 628 ALTIMMUNE: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 429 TABLE 629 AMGEN INC.: COMPANY OVERVIEW 430 TABLE 630 AMGEN INC.: PRODUCTS OFFERED (IN PIPELINE) 431 TABLE 631 GLENMARK PHARMACEUTICALS LTD.: COMPANY OVERVIEW 432 TABLE 632 GLENMARK PHARMACEUTICALS LTD.: PRODUCTS OFFERED (IN PIPELINE) 433 TABLE 633 GLENMARK PHARMACEUTICALS LTD.: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2025 433 TABLE 634 BIOCON: COMPANY OVERVIEW 434 TABLE 635 BIOCON: PRODUCTS OFFERED (IN PIPELINE) 435 TABLE 636 BIOCON: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025 436 TABLE 637 BIOCON: DEALS, JANUARY 2022–SEPTEMBER 2025 436 TABLE 638 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 438 TABLE 639 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED (IN PIPELINE) 439 TABLE 640 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2025 439 TABLE 641 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 440 TABLE 642 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED (IN PIPELINE) 441 TABLE 643 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–SEPTEMBER 2025 442 TABLE 644 TERNS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 443 TABLE 645 METAVIA: COMPANY OVERVIEW 443   TABLE 646 SCOHIA PHARMA, INC.: COMPANY OVERVIEW 444 TABLE 647 REGOR THERAPEUTICS GROUP: COMPANY OVERVIEW 444 TABLE 648 NEURALY INC.: COMPANY OVERVIEW 445 TABLE 649 I2O THERAPEUTICS, INC.: COMPANY OVERVIEW 445 TABLE 650 PFIZER INC.: COMPANY OVERVIEW 446 TABLE 651 HANMI PHARM CO., LTD.: COMPANY OVERVIEW 446 TABLE 652 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW 447 TABLE 653 BIOMED INDUSTRIES, INC.: COMPANY OVERVIEW 447 FIGURE 1 GLP-1 AGONISTS MARKET SEGMENTATION & REGIONAL SCOPE 43 FIGURE 2 GLP-1 AGONISTS MARKET: YEARS CONSIDERED 45 FIGURE 3 GLP-1 AGONISTS MARKET: RESEARCH DESIGN 48 FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 50 FIGURE 5 GLP-1 AGONISTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 51 FIGURE 6 GLP-1 AGONISTS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2024 51 FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 52 FIGURE 8 GLP-1 AGONISTS MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 53 FIGURE 9 CAGR PROJECTIONS: GLP-1 AGONISTS MARKET, 2025–2033 54 FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN GLP-1 AGONISTS MARKET 55 FIGURE 11 GLP-1 AGONISTS MARKET: DATA TRIANGULATION METHODOLOGY 56 FIGURE 12 GLP-1 AGONISTS MARKET, BY PRODUCT, 2025 VS. 2033 (USD BILLION) 58 FIGURE 13 GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2033 (USD BILLION) 59 FIGURE 14 GLP-1 AGONISTS MARKET, BY INDICATION, 2025 VS. 2030 (USD BILLION) 59 FIGURE 15 GLP-1 AGONISTS MARKET, BY END USER, 2025 VS. 2030 (USD BILLION) 60 FIGURE 16 REGIONAL SNAPSHOT OF GLP-1 AGONISTS MARKET 61 FIGURE 17 INCREASING PREVALENCE OF TYPE-2 DIABETES AND OBESITY TO PROPEL MARKET GROWTH 64 FIGURE 18 US AND DIABETES DOMINATED NORTH AMERICAN MARKET IN 2024 65 FIGURE 19 SINGLE-DOSE FORMATS ACCOUNTED FOR LARGEST GLP-1 AGONISTS FORMAT MARKET SHARE IN 2024 65 FIGURE 20 HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 66 FIGURE 21 KINGDOM OF SAUDI ARABIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 66 FIGURE 22 GLP-1 AGONISTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 71 FIGURE 23 US: PREVALENCE OF INDICATIONS THAT RESPOND TO GLP-1 DRUGS (AS OF JANUARY 2024) 74 FIGURE 24 GLP-1 AGONISTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 78 FIGURE 25 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 80 FIGURE 26 GLP-1 AGONISTS MARKET: VALUE CHAIN ANALYSIS 92 FIGURE 27 GLP-1 AGONISTS MARKET: ECOSYSTEM ANALYSIS 94 FIGURE 28 GLP-1 AGONISTS MARKET: PORTER’S FIVE FORCES ANALYSIS 95 FIGURE 29 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GLP-1 AGONISTS, BY TYPE 101 FIGURE 30 KEY BUYING CRITERIA FOR END USERS 102 FIGURE 31 AI USE CASES IN GLP-1 AGONISTS MARKET 106 FIGURE 32 NORTH AMERICA: GLP-1 AGONISTS MARKET SNAPSHOT 251 FIGURE 33 ASIA PACIFIC: GLP-1 AGONISTS MARKET SNAPSHOT 298 FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET, 2020–2024 (USD BILLION) 377 FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET (2024) 378 FIGURE 36 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 380 FIGURE 37 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2024 382 FIGURE 38 GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (KEY PLAYERS) 383 FIGURE 39 GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (PRODUCTS IN PIPELINE) 383 FIGURE 40 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 388 FIGURE 41 EV/EBITDA OF KEY VENDORS 391 FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 391 FIGURE 43 GLP-1 AGONISTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 392 FIGURE 44 NOVO NORDISK A/S: COMPANY SNAPSHOT 397 FIGURE 45 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 403 FIGURE 46 SANOFI: COMPANY SNAPSHOT 407 FIGURE 47 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: COMPANY SNAPSHOT 409 FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT 412 FIGURE 49 INNOVENT: COMPANY SNAPSHOT 414 FIGURE 50 ZEALAND PHARMA: COMPANY SNAPSHOT 420 FIGURE 51 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT 425 FIGURE 52 AMGEN INC.: COMPANY SNAPSHOT 431 FIGURE 53 GLENMARK PHARMACEUTICALS LTD.: COMPANY SNAPSHOT 432 FIGURE 54 BIOCON: COMPANY SNAPSHOT 435 FIGURE 55 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT 438 FIGURE 56 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 441

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們